Compound ID | 1245

Update compound information

RC-01, T-1228

Class: Lipopolysaccharide synthesis inhibitor (LpxC inhibitor)

Spectrum of activity: Gram-negative
Details of activity: Activity against gram-negative bacteria, including MDR Enterobacteriaceae and P. aeruginosa
Institute where first reported: Recida Therapeutics; Fujifilm Toyama Chemical Co. Ltd. (Toyoma, Japan)
Highest developmental phase: Phase 1
Development status: Inactive
Reason Dropped: Toxicity; prematurely terminated
External links:
Citations:
  • https://carb-x.org/carb-x-news/carb-x-funds-recida-therapeutics-to-develop-a-new-class-of-antibiotics-to-treat-deadly-infections-caused-by-gram-negative-superbugs/
  • https://catalyspacific.com/2019/04/01/recida-therapeutics-announces-the-initiation-of-a-phase-i-clinical-trial-of-rc-01-a-novel-lpxc-inhibitor/

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.